Three major players will try to recover costs from Pan Pharmaceuticals after Australia's largest ever medical products recall, reports IndustrySearch.com.
According to the article, the Mayne group, Sigma and Australian Pharmaceutical Industries (API) all said on Tuesday that they were looking to recuperate their costs, although none are believed to have launched legal action.
In April, the Therapeutic Goods Administration (TGA) suspended Pan's licence last month citing a series of safety and quality breaches. The TGA said breaches included the substitution of ingredients, manipulation of test results and substandard manufacturing processes.
As a result, more than 1,500 products manufactured by Pan - Australia's largest contract manufacturer of complementary pharmaceuticals - have since been recalled.
The report continues that Australian Health minister Kay Patterson could not confirm in parliament on Tuesday who would pay for refunds of medicines recalled as part of the Pan crisis. Labour Senator Michael Forshaw is cited as saying there was growing evidence of health food stores and pharmacies failing to provide refunds on products because of doubts about the capacity of Pan Pharmaceuticals to fund them